lessthanhalf said:
sofaKINGnoob said:
lastresort said:
At 1 and 2 mg, I'm handling it fine...I'll continue posting updates.
The Lipodrene I mentioned comes from Hi Tech Pharmaceutical, a supplement brand that also markets prohormones aimed at bodybuilders. Mine arrived as a free sample, and honestly that 1hr of "cardio high" isn't worth it, since your stamina gets wrecked for the remainder of the day.
I'll be honest....with zero clinical trials out there, I'm basically fumbling around in the dark with this stuff.
I came across claims that this compound behaves like a milder DNP.... and that's not a positive comparison. Rather than running more experiments, why not simply use reta the way most of us do to shed some weight?
DNP carries serious risk because its therapeutic index is narrow — the gap separating an effective dose from a lethal one is quite small, and that is exactly why fatalities occur.
Compared with DNP, Bam15 uncouples mitochondria less potently, so at large doses it is far less likely to kill. Even so, no human dosing has ever been established, since human studies simply do not exist. Considering what kind of drug this is, its mechanism, and how preliminary the research remains — even in animal models — using it is nowhere near low risk. There are zero human dosing-safety studies, and the animal work that must precede any human study has not been completed either, including toxicity and carcinogenesis testing.
It is still under development as a drug candidate. However, pharmaceutical companies specifically pursue mitochondrial uncouplers that act only in the liver rather than throughout the body, aiming to lower the odds of severe adverse events or off-target effects. In fact, a prodrug form of DNP is being developed, designed to convert into DNP solely within the liver and act there — and that program is likely further along than bam15.
From the animal data, Bam15 certainly appears promising. Still, I do not consider it ready for human testing, whether in formal trials or by self-selected guinea pigs. Reta has not been approved yet, but it already has substantial human clinical trial data and is clearly the safer choice.
